论文部分内容阅读
集高科技、新产品、新机制为一体的中国科学院成都地奥制药公司,既是以开发国家级新药“地奥心血康”蜚声海内外,又是以先进科技成果、高新技术产品为支柱的科技型经济实体。目前形成了具有国际竞争能力的高技术产品开发环境,成为拥有净资产1.8亿元,年利税近1亿元的大型制药企业,是国内目前实力最强的新药开发生产基地之一。 1982年,以李伯刚为组长的中国科学院成都生物研究所“地奥心血康”课题组,承担了中国科学院“六五”和“七五”重点科研课题、防治心血管疾病植物
The Chinese Academy of Sciences Chengdu Diao Pharmaceutical Company, which integrates high-tech, new products, and new mechanisms, is a science and technology economic entity based on the development of a state-level new drug, “Dioxue Kangxuexue”, which is based on advanced scientific and technological achievements and high-tech products. . At present, it has formed a high-tech product development environment with international competitiveness. It has become a large-scale pharmaceutical company with net assets of 180 million yuan and annual profits and taxes of nearly 100 million yuan. It is currently one of the strongest new drug development and production bases in China. In 1982, the research group “Duoaoxinxuekang” of Chengdu Institute of Biology, headed by Li Bogang, undertook the “Sixth Five-Year” and “Seventh Five-Year” key scientific research topics of the Chinese Academy of Sciences and the prevention and treatment of cardiovascular disease plants.